This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Direct quality control of glycoengineered erythropoietin variants
Nature Communications Open Access 21 August 2018
-
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
BioDrugs Open Access 13 January 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dorey, E. Nat. Biotechnol. 31, 774 (2013).
European Medicines Agency. CHMP Assessment Report for Filgrastim Hexal. (no. EMEA/CHMP/651324/2008) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000918/WC500022471.pdf (2008).
European Medicines Agency. European Public Assessment Report for Binocrit. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf (2007).
European Medicines Agency. CHMP Assessment Report for Remsima. (no. EMA/CHMP/589317/2013) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf (2013).
European Medicines Agency. CHMP Draft Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. (no. CHMP EMEA/CHMP/BMWP/42832/2005, rev. 1) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.S. is a member of the advisory boards on biosimilars of Amgen, Pfizer and Merck-Serono.
Rights and permissions
About this article
Cite this article
Schellekens, H., Moors, E. Biosimilars or semi-similars?. Nat Biotechnol 33, 19–20 (2015). https://doi.org/10.1038/nbt.3083
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3083
This article is cited by
-
Direct quality control of glycoengineered erythropoietin variants
Nature Communications (2018)
-
Celltrion's infliximab copy shows path to biosimilars in US
Nature Biotechnology (2016)
-
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
BioDrugs (2016)